Inactive Instrument

News Acarix AB (publ) Nasdaq Stockholm

Equities

SE0009268717

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Acarix AB’s Annual Report 2023	Apr. 23	AQ
NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB	Apr. 11	AQ
Acarix announces the initiation of the first US-based clinical workflow evaluation study	Apr. 11	AQ
Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study	Apr. 11	CI
Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review	Apr. 11	AQ
New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness	Apr. 08	AQ
Acarix Announces the Results from 2024 American College of Cardiology Poster Presentation to Assess the Cost-Utility of the Cadscor System	Apr. 08	CI
Acarix has submitted application for cross-trading at OTCQB in the US	Apr. 05	AQ
Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)	Mar. 20	AQ
Acarix receives declarations of intent to exercise warrants of series TO 2	Mar. 19	AQ
CEO purchases shares in Acarix	Mar. 15	AQ
The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today	Mar. 06	AQ
Announcement from Acarix's extra general meeting	Feb. 21	AQ
Acarix Q4 2023 - Soft ending to 2023 but gearing up for 202	Feb. 19	AQ
Transcript : Acarix AB, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Acarix Appoints New Members to the Advisory Board	Feb. 15	CI
Acarix strengthens US Advisory Board with three industry leaders	Feb. 15	AQ
Acarix AB (publ) publishes Year-End Report 2023	Feb. 15	AQ
Acarix AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Acarix AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Acarix AB (publ) Nasdaq Stockholm

Equities

SE0009268717

Summary

Filters